 |
Journal articles
Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.
Aurelien Delluc 1, 2
Mail :
Correspondent author
Elisabeth Pasquier 1, 2
Author
Luc de Saint Martin 1, 2
Author
Dominique Mottier 1
Author
1
GETBO - Groupe d'Etude de la Thrombose de Bretagne Occidentale (CHU de la Cavale Blanche Département de médecine interne et pneumologie 29609 BREST - France)
- UBO - Université de Brest (Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest - France)
- IBSAM - Institut Brestois Santé Agro Matière (Université de Brest- UBO
29238 Brest - France)
- UBO - Université de Brest (Université de Bretagne Occidentale - 3 Rue des Archives 29238, Brest - France)
Document type :
Journal articles
Domain :
Complete list of metadatas
https://hal.univ-brest.fr/hal-00689153
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, April 19, 2012 - 1:40:29 PM
Last modification on : Thursday, November 29, 2018 - 4:09:30 PM
Contributor : Ghislaine Calvez <>
Submitted on : Thursday, April 19, 2012 - 1:40:29 PM
Last modification on : Thursday, November 29, 2018 - 4:09:30 PM
Identifiers
- HAL Id : hal-00689153, version 1
- PUBMED : 16533732
Collections
UNIV-BREST | GETBO | IBSAM
Citation
Aurelien Delluc, Elisabeth Pasquier, Luc de Saint Martin, Dominique Mottier. Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use.. Haematologica, Ferrata Storti Foundation, 2006, 91 (3), pp.ECR05. ⟨hal-00689153⟩
Metrics
Record views
